Using a new PFD3 PET tracer to find and stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1/2 interventional study gives enrolled adults with histologically confirmed SCLC sequential PET/CT scans using standard [18F]-FDG and the investigational [68Ga]-PFD3 tracer to compare imaging performance and safety. The protocol focuses on patients with at least one measurable lesion and includes laboratory monitoring and imaging-based endpoints. Primary goals include characterizing PFD3 safety and measuring how well it identifies tumor sites and distinguishes limited- from extensive-stage disease compared with FDG. The work is being conducted at a single center (Peking University First Hospital, Beijing) and excludes patients who previously received DLL3-targeted therapy or who cannot undergo PET scanning.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults.
* Histologically confirmed small cell lung cancer (SCLC).
* At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.
* Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.

Exclusion Criteria:

* Pregnancy.
* Breastfeeding.
* Acute psychiatric disorders.
* Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).
* Inability to complete the study procedures as anticipated.
* Prior therapy targeting DLL3.

Where it's running

• Peking university first hospital nuclear medicine
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Tingting Yuan, M. D.
• Email: biluohtt@163.com
• Phone: +86-13051707479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

  This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07795411

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• Adaptive Phase 1/2 testing dual-target CAR‑NK cells for relapsed or refractory small cell lung cancer

  This trial tests off-the-shelf dual-target CAR‑NK cell therapy in adults with relapsed or refractory extensive-stage small cell lung cancer to see if it is safe and can shrink tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07480213

• PF-08634404 with or without chemotherapy for adults with transformed small cell lung cancer

  This will try the experimental drug PF-08634404 by itself and together with chemotherapy in adults whose EGFR-mutated non-small cell lung cancer has turned into transformed small cell lung cancer.

  Recruiting at 55 sites Phase 2 Pfizer · Duarte, California and 60 other locations · NCT07476287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.